For years, India did not recognise patents on drugs, which allowed India's generics drugs industry to flourish.
In a statement issued following the ruling, Novartis called the decision "a setback for patients".
Novartis has threatened that if it lost the case, it would not introduce its newest generation of medicines to India.
